• PCN19 Effectiveness and Medical Costs of Abiraterone Acetate Versus Docetaxel in First-LINE Treatment of Metastatic Castration-Resistant Prostate Cancer from the French Nationwide Claims Database (SNDS): Camerra Study

    Dec 1, 2020, 00:00

  • HTA2 Joint HTA in Europe to What Extent Are Reports Meeting Agency NEEDS?

    Dec 1, 2020, 00:00

  • PCN71 Budget IMPACT Analysis of Zanubrutinib for the Treatment of Adult Patients with Mantle Cell Lymphoma WHO Have Received at Least One PRIOR Therapy from the Payer Perspective in the United States

    Dec 1, 2020, 00:00

  • PBI3 Comparative Efficacy of Guselkumab and Tildrakizumab in Moderate-to-Severe Plaque Psoriasis: A Matching-Adjusted Indirect Comparison

    Dec 1, 2020, 00:00

  • PCN103 Cost-Effectiveness Analysis of Trastuzumab Emtansine for Adjuvant Treatment of Adult Patients with HER2+ EARLY Breast Cancer in Turkey

    Dec 1, 2020, 00:00

  • PCN48 Adapting Preference-Based Utility Measures to Capture the Impact of Cancer Treatment-Related Symptoms

    Dec 1, 2020, 00:00

  • PBI10 Cost Effectiveness Analysis for the Treatment of Psoriasis: The Use of Adalimumab Biosimilars

    Dec 1, 2020, 00:00

  • PCN94 Cost-Effectiveness of Trifluridine/Tipiracil (FTD/TPI) As a Third-LINE Treatment of Metastatic Gastric Cancer, Including Adenocarcinoma of the Gastroesophageal Junction, Among Patients WHO Have Received at Least Two PRIOR Therapies fo ...

    Dec 1, 2020, 00:00

  • PCN97 Budget IMPACT of Oncotype DX GPS ASSAY in Patients with Localized Prostate Cancer in Germany

    Dec 1, 2020, 00:00

  • PBI32 Fulfilling the Potential of Best-VALUE Biological Medicines in Belgium

    Dec 1, 2020, 00:00

  • PCN107 Cost-Effectiveness Analysis of Lorlatinib in Patients Previously Treated with Anaplastic Lymphoma Kinase Inhibitors for NON-SMALL CELL LUNG Cancer in Greece

    Dec 1, 2020, 00:00

  • PCN130 Modeling Approaches in Cost-Effectiveness Analysis (CEA) of First-Line (1L) Immuno-Oncology (IO) Therapies in Non-Small Cell Lung Cancer (NSCLC): A Systematic Literature Review (SLR)

    Dec 1, 2020, 00:00

  • PCN11 Non-Adherence To Oral Treatments In Patients With Multiple Myeloma: Real-World Evidence From A German Claims Data

    Dec 1, 2020, 00:00

  • Alternative Medicine Nutrition - Patient-Centered Research

    Dec 1, 2020, 00:00

  • PCN102 Healthcare Resource Utilization (HCRU) and Costs with Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors (EGFR TKIS) and Subsequent Chemotherapy Among Patients with LUNG Cancer

    Dec 1, 2020, 00:00

  • PCN104 Cost-Utility MODEL of Trastuzumab Emtansine (T-DM1) in HER2-Positive, Unresectable, Locally Advanced or Metastatic Breast Cancer Previously Treated with Trastuzumab and a Taxane, Compared with Capecitabine PLUS Lapatinib, Trastuzumab ...

    Dec 1, 2020, 00:00

  • ML3 Detection of Quality of Life IMPACT in Health-Related Messages in Social MEDIA

    Dec 1, 2020, 00:00

  • PCN91 Estimating EQ-5D Utilities for Cost-Effectiveness Models Involving Immuno-Oncology Treatments

    Dec 1, 2020, 00:00

  • PBI20 Evaluation of Published Models in Sickle Cell Disease Against Key Criteria for an Economic Model for a Potentially Curative One-Time Treatment

    Dec 1, 2020, 00:00

  • PCN144 The Comparative Pharmacoeconomic Analysis of Using Cabozantinib As Second-LINE Therapy for Adult Patients with Metastatic Renal Cell Carcinoma in Russia

    Dec 1, 2020, 00:00

  • PCN42 Real-World Effectiveness in Previously Untreated, Advanced/Metastatic Renal Cell Carcinoma – a Systematic Literature Review Update

    Dec 1, 2020, 00:00

  • CL2 Measuring Health-Related Quality of Life in the Context of Episodic Conditions

    Dec 1, 2020, 00:00

  • PCN118 Budget IMPACT Analysis of Inotuzumab Ozogamicin for the Treatment of Adults with Relapsed or Refractory B-Cell Precursor ACUTE Lymphoblastic Leukemia in the Netherlands

    Dec 1, 2020, 00:00

  • PBI12 Budget Impact Analysis of Baricitinib for the Management of Moderate-to-Severe Rheumatoid Arthritis in the Kingdom of Saudi Arabia

    Dec 1, 2020, 00:00

  • Access and Unmet Needs of Orphan Drugs in 194 Countries and 6 Areas: A Global Policy Review With Content Analysis (Editor's Choice)

    Dec 1, 2020, 00:00

  • PCN133 Disease Burden of Hodgkin's Lymphoma in Fran A Descriptive Study Based on a French Medico-Administrative Database

    Dec 1, 2020, 00:00

  • PCN76 Evaluating Trends In Direct Healthcare Costs In The Last Year Of Life Among Patients With Lung Cancer In Germany

    Dec 1, 2020, 00:00

  • NM3 Extending the Network Meta-Analysis (NMA) Framework to Multilevel Network Meta-Regression (ML-NMR): A Worked Example of ML-NMR VS Standard NMA

    Dec 1, 2020, 00:00

  • IN4 Economic Impact of Routine Childhood Immunization in the 2017 United States Birth Cohort

    Dec 1, 2020, 00:00

  • PCN18 Matching-Adjusted Indirect Comparison (MAIC) of Entrectinib Versus Crizotinib in Patients with ROS1 NON-SMALL CELL LUNG Cancer (NSCLC): An Updated Analysis

    Dec 1, 2020, 00:00

  • ON2 Assessing the Performance of Landmark Response Analysis to Improve Overall Survival Extrapolation in Nivolumab NSCLC Trials

    Dec 1, 2020, 00:00

  • PCN69 Cost-Effectiveness Analysis of NOVEL Therapies for HER2+ Metastatic Breast Cancer: [FAM-] Trastuzumab Deruxtecan Versus Tucatinib Trastuzumab and Capecitabine Combination

    Dec 1, 2020, 00:00

  • PCN3 IMPACT of COVID-19 on Immunotherapy Utilization in Metastatic NON-SMALL Cell LUNG Cancer

    Dec 1, 2020, 00:00

  • PBI46 Cost-Effectiveness of Treatment Sequences Initiating with Risankizumab for the Treatment of Moderate to Severe Psoriasis in Portugal

    Dec 1, 2020, 00:00

  • Medical Technologies Studies

    Dec 1, 2020, 00:00

  • PBI21 The MOST Cost-Effective Approach to Prevent Complications in Young Patients Diagnosed with Sickle CELL Anemia from Employers Perspective Using Decision Tree MODEL

    Dec 1, 2020, 00:00

  • PCN89 A Cost-Effectiveness Analysis of Atezolizumab in Combination with Carboplatin and Etoposide in Patients with Untreated Extensive-Stage Small Cell Lung Cancer

    Dec 1, 2020, 00:00

  • PBI5 An Indirect Comparison of Sustained Remission and FLARE Rates in Responders with NON-Radiographic Axial Spondyloarthritis (NR-AXSPA)

    Dec 1, 2020, 00:00

  • PCN62 Budget IMPACT Analysis of Trastuzumab Emtansine for Residual Invasive HER2-Positive Breast Cancer in Argentina

    Dec 1, 2020, 00:00

  • Alternative Approaches to Quality-Adjusted Life-Year Estimation Within Standard Cost-Effectiveness Models: Literature Review, Feasibility Assessment, and Impact Evaluation (Editor's Choice)

    Dec 1, 2020, 00:00

  • ML4 Application of Machine Learning Models to Evaluate COVID-19 Related ICU Utilization in a US Population

    Dec 1, 2020, 00:00

  • PCN93 Cost-Effectiveness Analysis of DEB-TACE Compared to Lipiodol-TACE As First LINE Treatment for Unresectable HCC

    Dec 1, 2020, 00:00

  • Biologics/Biosimilars/Regenerative Medicine - Economic Evaluation

    Dec 1, 2020, 00:00

  • Developments in HTA Processes and Methods

    Dec 1, 2020, 00:00

  • PCN70 Cost Effectiveness Analysis of Pembrolizumab in the Treatment of Adults with STAGE III Melanoma and Lymph Node Involvement WHO Have Undergone Complete Resection - the Greek Setting

    Dec 1, 2020, 00:00

  • PBI4 Real World Treatment Patterns of Biologics in a Cohort of Ulcerative Colitis Patients

    Dec 1, 2020, 00:00

  • PCN110 Cost-Utility Analysis of Adjuvant Trastuzumab Emtansine Versus Trastuzumab in Patients with HER2+ EARLY Breast Cancer with Residual Invasive Disease after Neoadjuvant Therapy in Spain

    Dec 1, 2020, 00:00

  • PCN33 Chemotherapy Treatments for Burkitt Lymphoma: Systematic Review of Interventional Studies

    Dec 1, 2020, 00:00

  • Association Between Filgrastim Biosimilar Availability and Changes in Claim Payments and Patient Out-of-Pocket Costs for Biologic Filgrastim Products

    Dec 1, 2020, 00:00

  • PCN115 Economic Evaluation of Artificial Intelligence-Assisted Colonoscopy for Routine Screening of Low- to High-Risk Colorectal Cancer Patients in the United Kingdom

    Dec 1, 2020, 00:00

  • PBI55 Patient Preferences for GENE Therapy in Hemophilia: Results from the Paving Threshold Technique Survey

    Dec 1, 2020, 00:00

  • PCN139 Cost per Consequence Analysis of Erdafinitib and ANTI-PD1/PDL1 Therapies for Metastatic Urothelial Carcinoma FGFR+ from the Perspective of Brazilian Private Health System

    Dec 1, 2020, 00:00

  • PAM7 Preferences of Adults Regarding Personalized Nutrition Interventions: A FOCUS Group Study

    Dec 1, 2020, 00:00

  • PBI23 Cost Saving Opportunity for the Treatment of Psoriasis: The Use of Adalimumab Biosimilars

    Dec 1, 2020, 00:00

  • PBI14 Budget IMPACT Analysis of a Reduced Maintenance Dose of Certolizumab Pegol in Patients with Axial Spondyloarthritis in the United Kingdom

    Dec 1, 2020, 00:00

  • PCN58 Metastatic Renal Carcinoma Costs in Slovakia: Analysis of Direct and Indirect Costs in 2018

    Dec 1, 2020, 00:00

  • PCN23 Overall Survival Estimates Adjusting for Treatment Crossover in Patients Previously Untreated with an ALK Inhibitor with ALK+ NSCLC Using DATA from the Alta-1L Clinical Trial

    Dec 1, 2020, 00:00

  • PCN85 An Updated Cost-Utility Analysis in Italian Patients of Entrectinib Compared to Standard of Care in NTRK+ Tumor Agnostic Indication

    Dec 1, 2020, 00:00

  • PA2 Treatment Intensification and Risk of Cardiovascular Events in Insulin-Treated Patients with Type 2 Diabetes; A United Kingdom Retrospective Cohort Study

    Dec 1, 2020, 00:00

  • PCN10 Real-World Hospital Outcomes Versus Clinical Trial Outcomes of Systemic Palliative Treatments for Melanoma STAGE III-IV Patients, with Wild-Type BRAF600 in the Netherlands

    Dec 1, 2020, 00:00

  • PCN64 Cost-Effectiveness of Pembrolizumab (KEYTRUDA®) in Combination with Chemotherapy for First-LINE Treatment of Metastatic Squamous NON-SMALL Cell LUNG Cancer (NSCLC) in France

    Dec 1, 2020, 00:00

  • PCN68 An Incremental Effectiveness Analysis of Lorlatinib for the Treatment of ALK-Positive Advanced Non-Small Cell Lung Cancer that has Progressed after Another ALK Tyrosine Kinase Inhibitor in Portugal

    Dec 1, 2020, 00:00

  • PBI35 Local Policies on Biosimilars: Are They Designed to Optimize Use of Freed Resources?

    Dec 1, 2020, 00:00

  • PCN40 Healthcare Resource Utilization in Patients Treated with Encorafenib PLUS Binimetinib for BRAF-Mutant Metastatic Melanoma: DATA from Columbus, a Phase 3 Trial in BRAF-Mutant Melanoma

    Dec 1, 2020, 00:00

  • PCN75 Direct Medical Cost of Breast Cancer in Saudi Arabia

    Dec 1, 2020, 00:00

  • PCN142 Multiple Myeloma in Portugal: Burden of Disease and Cost of Illness

    Dec 1, 2020, 00:00

  • PCN9 Effectiveness of Alectinib in a Real-World US Cohort

    Dec 1, 2020, 00:00

  • PCN72 Biomarker Testing to Guide Cost Effective Use of PARPi in Patients with Newly Diagnosed Ovarian Cancer

    Dec 1, 2020, 00:00

  • Adherence, Engagement, and Patient Behavior

    Dec 1, 2020, 00:00

  • PBI48 Overview of GENE Therapy Pricing Policies and Reimbursement Models in the EU-5 (GERMANY, UK, FRANCE, ITALY AND SPAIN)

    Dec 1, 2020, 00:00

  • PBI11 Cost-Effectiveness Analysis of Dupilumab for the Treatment of Atopic Dermatitis in Adolescent Patients in Italy

    Dec 1, 2020, 00:00

  • PBI47 Innovative Approaches for Patient Access to Gene Therapies in Haemophilia

    Dec 1, 2020, 00:00

  • PCN136 Cost-Effectiveness Analysis of Dacomitinib Versus Gefitinib for the First-line Treatment of Locally Advanced or Metastatic Non-Small Cell Lung Cancer with Epidermal Growth Factor Receptor (EGFR)-Activating Mutations in Portugal

    Dec 1, 2020, 00:00

  • PCN47 Utilisation and Perception of Indirect and Mixed Treatment Comparisons in NICE Technology Appraisals for Interventions Treating Multiple Myeloma

    Dec 1, 2020, 00:00

  • Issues in HEOR - Cardiovascular Disease and Diabetes

    Dec 1, 2020, 00:00

  • Cost-Effectiveness of Testing and Treatment for Hepatitis B Virus and Hepatitis C Virus Infections: An Analysis by Scenarios, Regions, and Income

    Dec 1, 2020, 00:00

  • PCN90 Economic IMPACT of the NSCLC Molecular Diagnosis in Spain: A Retrospective Analysis of Healthcare Resources Use and Associated Costs from the LUNG-One Study

    Dec 1, 2020, 00:00

  • A Cost-Effectiveness Framework for Amyotrophic Lateral Sclerosis, Applied to Riluzole

    Dec 1, 2020, 00:00

  • EX2 Structural Uncertainty in Survival Extrapolation: Exploring the IMPACT of FOUR MODEL Averaging Methods and Adjusting for DATA Maturity

    Dec 1, 2020, 00:00

  • PCN101 Budget IMPACT Analysis of Treatment-Free Remission (TFR) of Nilotinib Therapy in Chronic Myeloid Leukemia (CML) Patients in the Brazilian Private Healthcare System (BPHS)

    Dec 1, 2020, 00:00

  • PCN4 Overall Survival in Post-Menopausal Women with HR+/HER2- Advanced Breast Cancer Receiving a CDK 4 and 6 Inhibitor + Fulvestrant after Progressing on/after Prior Endocrine Therapy: A Fractional Polynomial Network Meta-Analysis

    Dec 1, 2020, 00:00

  • Alternative Medicine Nutrition - Medical Technologies

    Dec 1, 2020, 00:00

  • PBI6 Stringent Thresholds of Disease Control Are Associated with Reduced Burden on Paid and Household Work Productivity in Patients with Psoriatic Arthritis during LONG-TERM Treatment with Certolizumab Pegol

    Dec 1, 2020, 00:00

  • PCN54 Measuring the Economic, Societal, and Organizational IMPACT of Personalized Healthcare in Oncology

    Dec 1, 2020, 00:00

  • PCN80 A Case Study in Molecular Diagnostic: A Comparison between an NGS-Based Approach Versus a Single-GENE Testing Approach in Ansclc and Mcrc Patients for an Italian Hospital

    Dec 1, 2020, 00:00

  • PCN128 Utility Weight Considerations in Nice Immune Checkpoint Inhibitor Oncology Appraisals

    Dec 1, 2020, 00:00

  • CO2 WHEN Could a Second Wave of COVID-19 Appear in Germany and How Strong Will IT be? a Simulation Analysis

    Dec 1, 2020, 00:00

  • PCN2 First-LINE Maintenance and Second-LINE Treatment of Advanced or Metastatic Gastric Cancer: A Systematic Review of Literature

    Dec 1, 2020, 00:00

  • PCN86 Healthcare Costs and Resource Utilization Associated with PARP Inhibitors in Ovarian Cancer Patients Initially Treated with Platinum-Based Therapy

    Dec 1, 2020, 00:00

  • PBI29 Does Short-Term Gain Lead to Longer Term Pain ? the Case for Developing a Sustainable Biosimilar Marketplace

    Dec 1, 2020, 00:00

  • PCN82 Budget Impact Analysis of Subcutaneous Daratumumab for the Treatment of Patients with Multiple Myeloma in Sweden

    Dec 1, 2020, 00:00

  • PCN98 Scenarios of Cost-Savings Associated with Oncotype DX® Test - Guided Decisions for Adjuvant Chemotherapy in EARLY Breast Cancer in Germany

    Dec 1, 2020, 00:00

  • PCN99 Economic Evaluation of Artificial Intelligence-Assisted Colonoscopy for Routine Screening of High-Risk Colorectal Cancer Patients in Spain

    Dec 1, 2020, 00:00

  • Biologics/Biosimilars/Regenerative Medicine - Health Service Delivery Process of Care

    Dec 1, 2020, 00:00

  • PCN57 Budget IMPACT Analysis of Trifluridine/Tipiracil (FTD/TPI) As a Third-LINE Treatment of Metastatic Gastric Cancer, Including Adenocarcinoma of the Gastroesophageal Junction, Among Patients WHO Have Received at Least Two PRIOR Therapie ...

    Dec 1, 2020, 00:00

  • PCN56 Brentuximab Vedotin PLUS CHP in Frontline Systemic Anaplastic Large Cell Lymphoma (SALCL): Adjusted Estimates of Efficacy and Cost-Effectiveness Removing the Effects of Retreatment with Brentuximab Vedotin

    Dec 1, 2020, 00:00

  • PCN123 5-Year Health Care Costs of Sepsis in Cancer Patients: Results from a Population-Based Case-Control Matched Cohort

    Dec 1, 2020, 00:00

  • PCN113 A Retrospective Cohort Study of the National Healthcare Resource Utilisation (HCRU) and Costs of Treating Multiple Myeloma (MM) in France Using the Système National DES Données De Santé (SNDS) Database

    Dec 1, 2020, 00:00

  • ON3 Comparison of External Control Arm (ECA) Critiques in Regulatory and Health Technology Assessment (HTA) Oncology Submissions

    Dec 1, 2020, 00:00

  • Reviewer Acknowledgment

    Nov 30, 2020, 18:29

  • Optimization Models for HIV/AIDS Resource Allocation: A Systematic Review

    Nov 1, 2020, 00:00

  • Table of Contents

    Nov 1, 2020, 00:00

  • The Economic and Public Health Imperatives Around Making Potential Coronavirus Disease–2019 Treatments Available and Affordable

    Nov 1, 2020, 00:00

  • Coronavirus Disease 2019: Considerations for Health Technology Assessment From the National Centre for Pharmacoeconomics Review Group

    Nov 1, 2020, 00:00

  • Assessment of Studies Evaluating Incremental Costs, Effectiveness, or Cost-Effectiveness of Systemic Therapies in Breast Cancer Based on Claims Data: A Systematic Review

    Nov 1, 2020, 00:00

  • Costing the COVID-19 Pandemic: An Exploratory Economic Evaluation of Hypothetical Suppression Policy in the United Kingdom

    Nov 1, 2020, 00:00

  • Being Precise About Precision Medicine: What Should Value Frameworks Incorporate to Address Precision Medicine? A Report of the Personalized Precision Medicine Special Interest Group

    Nov 1, 2020, 00:00

  • Cost-Effectiveness of Immediate Magnetic Resonance Imaging In the Management of Patients With Suspected Scaphoid Fracture: Results From a Randomized Clinical Trial

    Nov 1, 2020, 00:00

  • Informing Balanced Investment in Services and Health Systems: A Case Study of Priority Setting for Tuberculosis Interventions in South Africa [Editor's Choice]

    Nov 1, 2020, 00:00

  • Measuring “Fearonomic Effects” in Valuing Therapies: An Application to COVID-19 in China

    Nov 1, 2020, 00:00

  • Cost-Effectiveness of Antiviral Treatments for Pandemics and Outbreaks of Respiratory Illnesses, Including COVID-19: A Systematic Review of Published Economic Evaluations

    Nov 1, 2020, 00:00

  • Testing the “Nonstopping” Time Trade-Off: Is It Better Than the Composite Time Trade-Off?

    Nov 1, 2020, 00:00

  • Head-to-Head Comparison of the Psychometric Properties of 3 Carer-Related Preference-Based Instruments [Editor's Choice]

    Nov 1, 2020, 00:00

  • Willingness to Accept Trade-Offs Among COVID-19 Cases, Social-Distancing Restrictions, and Economic Impact: A Nationwide US Study [Editor's Choice]

    Nov 1, 2020, 00:00

  • Modifying the Criteria for Granting Orphan Drug Market Exclusivity

    Nov 1, 2020, 00:00

  • Copyright/Subscription

    Nov 1, 2020, 00:00

  • The Role of Health Economics and Outcomes Research in Addressing Coronavirus Disease 2019 (COVID-19)

    Nov 1, 2020, 00:00

  • Practical Guidance for Including Future Costs in Economic Evaluations in The Netherlands: Introducing and Applying PAID 3.0 [Editor's Choice]

    Nov 1, 2020, 00:00

  • Editorial Board

    Oct 27, 2020, 09:56

  • Editorial Board

    Oct 7, 2020, 17:37

  • Do Discrete Choice Experiments Approaches Perform Better Than Time Trade-Off in Eliciting Health State Utilities? Evidence From SF-6Dv2 in China

    Oct 1, 2020, 00:00

  • Economic Evaluation of Factorial Trials: Cost-Utility Analysis of the Atorvastatin in Factorial With Omega EE90 Risk Reduction in Diabetes 2 × 2 × 2 Factorial Trial of Atorvastatin, Omega-3 Fish Oil, and Action Planning

    Oct 1, 2020, 00:00

  • Costs of Early Invasive Breast Cancer in England Using National Patient-Level Data

    Oct 1, 2020, 00:00

  • Trade-Offs in Quality-of-Life Assessment Between the Modified Rankin Scale and Neuro-QoL Measures

    Oct 1, 2020, 00:00

  • Table of Contents

    Oct 1, 2020, 00:00

  • Willingness to Pay for Health Improvements Using Stated Preferences: Prevention Versus Treatment [Editor's Choice]

    Oct 1, 2020, 00:00

  • Cost-Effectiveness of Ivacaftor Therapy for Treatment of Cystic Fibrosis Patients With the G551D Gating Mutation

    Oct 1, 2020, 00:00

  • Health-Related Quality of Life in Neurological Disorders Most Commonly Associated With Zika-Virus Infection: A Systematic Review

    Oct 1, 2020, 00:00

  • Patient Preferences in Surveillance: Findings From a Discrete Choice Experiment in the “My Follow-Up” Study

    Oct 1, 2020, 00:00

  • How Good Is Machine Learning in Predicting All-Cause 30-Day Hospital Readmission? Evidence From Administrative Data

    Oct 1, 2020, 00:00

  • Evaluation of the National Institute for Health and Care Excellence Diagnostics Assessment Program Decisions: Incremental Cost-Effectiveness Ratio Thresholds and Decision-Modifying Factors [Editor's Choice]

    Oct 1, 2020, 00:00

  • Use of Real-World Evidence to Support FDA Approval of Oncology Drugs [Editor's Choice]

    Oct 1, 2020, 00:00

  • Inclusion of Carer Health-Related Quality of Life in National Institute for Health and Care Excellence Appraisals

    Oct 1, 2020, 00:00

  • Effects of Intravenous Golimumab on Health-Related Quality of Life in Patients with Ankylosing Spondylitis: 28-Week Results of the GO-ALIVE Trial

    Oct 1, 2020, 00:00

  • Is Multicriteria Decision Analysis a Resource Allocation Framework?

    Oct 1, 2020, 00:00

  • Effects of Intravenous Golimumab on Health-Related Quality of Life in Patients With Psoriatic Arthritis: 24-Week Results of the GO-VIBRANT Trial

    Oct 1, 2020, 00:00

  • Copyright/Subscription

    Oct 1, 2020, 00:00

  • Cost of Human Immunodeficiency Virus (HIV) and Determinants of Healthcare Costs in HIV-Infected Treatment-Naive Patients Initiated on Antiretroviral Therapy in Germany: Experiences of the PROPHET Study

    Oct 1, 2020, 00:00

  • Cost-Effectiveness of First-Line Tyrosine Kinase Inhibitor Therapy Initiation Strategies for Chronic Myeloid Leukemia

    Oct 1, 2020, 00:00

  • Spending on Hepatitis C Antivirals in the United States and Canada, 2014 to 2018

    Sep 1, 2020, 00:00

  • Effect of Case-Mix and Random Variation on Breast Cancer Care Quality Indicators and Their Rankability

    Sep 1, 2020, 00:00

  • Cost-Utility Analysis of Direct-Acting Antivirals for Treatment of Chronic Hepatitis C Genotype 1 and 6 in Vietnam

    Sep 1, 2020, 00:00

  • Competencies for Professionals in Health Economics and Outcomes Research: The ISPOR Health Economics and Outcomes Research Competencies Framework

    Sep 1, 2020, 00:00

  • Improving Transparency to Build Trust in Real-World Secondary Data Studies for Hypothesis Testing—Why, What, and How: Recommendations and a Road Map from the Real-World Evidence Transparency Initiative [Editor's Choice]

    Sep 1, 2020, 00:00

  • Taking Steps Toward Transparency in Real-World Evidence Studies

    Sep 1, 2020, 00:00

  • Editorial Board

    Sep 1, 2020, 00:00

  • Evaluating the Ability of Economic Models of Diabetes to Simulate New Cardiovascular Outcomes Trials: A Report on the Ninth Mount Hood Diabetes Challenge [Editor's Choice]

    Sep 1, 2020, 00:00

  • Applying Risk-Based Follow-Up Strategies on the Dutch Breast Cancer Population: Consequences for Care and Costs

    Sep 1, 2020, 00:00

  • Table of Contents

    Sep 1, 2020, 00:00

  • Parallel Valuation of the EQ-5D-3L and EQ-5D-5L by Time Trade-Off in Hungary

    Sep 1, 2020, 00:00

  • Demand for Cancer Screening Services: Results From Randomized Controlled Discrete Choice Experiments

    Sep 1, 2020, 00:00

  • Copyright/Subscription

    Sep 1, 2020, 00:00

  • From Multiple Quality Indicators of Breast Cancer Care Toward Hospital Variation of a Summary Measure

    Sep 1, 2020, 00:00

  • What Is a Valid Mapping Algorithm in Cost-Utility Analyses? A Response From a Missing Data Perspective

    Sep 1, 2020, 00:00

  • Association Between Medication Adherence and Healthcare Costs Among Patients Receiving the Low-Income Subsidy

    Sep 1, 2020, 00:00

  • Nephrologist Follow-Up Care of Patients With Acute Kidney Disease Improves Outcomes: Taiwan Experience

    Sep 1, 2020, 00:00

  • Are We Making a Difference? A Qualitative Study of Patient Engagement at the pan-Canadian Oncology Drug Review: Perspectives of Patient Groups [Editor's Choice]

    Sep 1, 2020, 00:00

  • Health State Utility Values in Schizophrenia: A Systematic Review and Meta-Analysis

    Sep 1, 2020, 00:00

  • Are Unit Costs the Same? A Case Study Comparing Different Valuation Methods for Unit Cost Calculation of General Practitioner Consultations

    Sep 1, 2020, 00:00

  • Evaluating the Use of microRNA Blood Tests for Gastric Cancer Screening in a Stratified Population-Level Screening Program: An Early Model-Based Cost-Effectiveness Analysis

    Sep 1, 2020, 00:00

  • A Review of Methodological Considerations for Economic Evaluations of Gene Therapies and Their Application in Literature [Editor's Choice]

    Sep 1, 2020, 00:00

  • Editorial Board

    Aug 20, 2020, 11:12

  • Editorial Board

    Aug 4, 2020, 08:58

  • Quantification of Trauma Center Access Using Geographical Information System–Based Technology

    Aug 1, 2020, 00:00

  • Leveraging DICE (Discretely-Integrated Condition Event) Simulation to Simplify the Design and Implementation of Hybrid Models

    Aug 1, 2020, 00:00

  • Patient-Centered Care for Women: Delphi Consensus on Evidence-Derived Recommendations [Editor's Choice]

    Aug 1, 2020, 00:00

  • Clinical and Economic Outcomes of Genome Sequencing Availability on Containing a Hospital Outbreak of Resistant Escherichia coli in Australia

    Aug 1, 2020, 00:00

  • Normative Estimates and Agreement Between 2 Measures of Health-Related Quality of Life in Older People With Frailty: Findings From the Community Ageing Research 75+ Cohort

    Aug 1, 2020, 00:00

  • Improving Academic Biobank Value and Sustainability Through an Outputs Focus

    Aug 1, 2020, 00:00

  • An Economic Evaluation of the Cost-Effectiveness of Opt-Out Hepatitis B and Hepatitis C Testing in an Emergency Department Setting in the United Kingdom

    Aug 1, 2020, 00:00

  • Systematic Review of Economic Evaluations of Primary Caries Prevention in 2- to 5-Year-Old Preschool Children

    Aug 1, 2020, 00:00

  • Economic Evaluation of Interventions to Address Opioid Misuse: A Systematic Review of Methods Used in Simulation Modeling Studies [Editor's Choice]

    Aug 1, 2020, 00:00

  • ICER Value Framework 2020 Update: Recommendations on the Aggregation of Benefits and Contextual Considerations [Editor's Choice]

    Aug 1, 2020, 00:00

  • Individuals’ Preferences for Esophageal Cancer Screening: A Discrete Choice Experiment

    Aug 1, 2020, 00:00

  • Reporting Quality of Marginal Rates of Substitution in Discrete Choice Experiments That Elicit Patient Preferences

    Aug 1, 2020, 00:00

  • UK General Population Utility Values for the SIDECAR-D Instrument Measuring the Impact of Caring for People With Dementia

    Aug 1, 2020, 00:00

  • Identifying Adherence Patterns Across Multiple Medications and Their Association With Health Outcomes in Older Community-Dwelling Adults With Multimorbidity

    Aug 1, 2020, 00:00

  • Cured Today, Ill Tomorrow: A Method for Including Future Unrelated Medical Costs in Economic Evaluation in England and Wales [Editor's Choice]

    Aug 1, 2020, 00:00

  • Table of Contents

    Aug 1, 2020, 00:00

  • Copyright/Subscription

    Aug 1, 2020, 00:00

  • Bias in Mean Survival From Fitting Cure Models With Limited Follow-Up

    Aug 1, 2020, 00:00

  • Value of a QALY for France: A New Approach to Propose Acceptable Reference Values

    Aug 1, 2020, 00:00

  • Science or Art? Reproducibility of Health Preference Research

    Jul 1, 2020, 00:00

  • Nonproportional Hazards in Network Meta-Analysis: Efficient Strategies for Model Building and Analysis

    Jul 1, 2020, 00:00

  • Yes, Authorship Is Important

    Jul 1, 2020, 00:00

  • Mimicking Real-Life Decision Making in Health: Allowing Respondents Time to Think in a Discrete Choice Experiment

    Jul 1, 2020, 00:00

  • Mapping From Visual Acuity to EQ-5D, EQ-5D With Vision Bolt-On, and VFQ-UI in Patients With Macular Edema in the LEAVO Trial

    Jul 1, 2020, 00:00

  • Let’s Make Sure We Are Doing Authorship Right

    Jul 1, 2020, 00:00

  • Heterogeneous Patient Preferences for Modern Antiretroviral Therapy: Results of a Discrete Choice Experiment

    Jul 1, 2020, 00:00

  • Impact of Next Generation Sequencing on Clinical Practice in Oncology in France: Better Genetic Profiles for Patients Improve Access to Experimental Treatments

    Jul 1, 2020, 00:00

  • Health-Related Quality of Life in Neurological Disorders Most Commonly Associated With Zika-Virus Infection: A Systematic Review

    Jul 1, 2020, 00:00

  • Patient Preferences for Medications in Managing Type 2 Diabetes Mellitus: A Discrete Choice Experiment

    Jul 1, 2020, 00:00

  • Copyright/Subscription

    Jul 1, 2020, 00:00

  • The Preferred Qualities of Human Immunodeficiency Virus Testing and Self-Testing Among Men Who Have Sex With Men: A Discrete Choice Experiment

    Jul 1, 2020, 00:00

  • Estimation of an Instrument-Defined Minimally Important Difference in EQ-5D-5L Index Scores Based on Scoring Algorithms Derived Using the EQ-VT Version 2 Valuation Protocols [Editor's Choice]

    Jul 1, 2020, 00:00

  • Concepts and Instruments for Patient-Reported Outcome Assessment in Celiac Disease: Literature Review and Experts’ Perspectives

    Jul 1, 2020, 00:00

  • A Review of the Methods Used to Generate Utility Values in NICE Technology Assessments for Children and Adolescents

    Jul 1, 2020, 00:00

  • Patient Preferences in the Treatment of Hemophilia A: A Best–Worst Scaling Case 3 Analysis

    Jul 1, 2020, 00:00

  • Health Preference Research in Europe: A Review of Its Use in Marketing Authorization, Reimbursement, and Pricing Decisions—Report of the ISPOR Stated Preference Research Special Interest Group [Editor's Choice]

    Jul 1, 2020, 00:00

  • A Systematic Review and Meta-Analysis of Health Utilities in Patients With Chronic Hepatitis C

    Jul 1, 2020, 00:00

  • Instructions for Authors

    Jul 1, 2020, 00:00

  • EQ-5D–Derived Health State Utility Values in Hematologic Malignancies: A Catalog of 796 Utilities Based on a Systematic Review [Editor's Choice]

    Jul 1, 2020, 00:00

  • Peruvian Valuation of the EQ-5D-5L: A Direct Comparison of Time Trade-Off and Discrete Choice Experiments

    Jul 1, 2020, 00:00

  • Comparative Distributional Impact of Routine Immunization and Supplementary Immunization Activities in Delivery of Measles Vaccine in Low- and Middle-Income Countries

    Jul 1, 2020, 00:00

  • Table of Contents

    Jul 1, 2020, 00:00

  • Editorial Board

    Jun 15, 2020, 08:48

  • Letter to the Editor - Announcing the New Definition of Health Technology Assessment

    Jun 1, 2020, 00:00

  • Validity and Responsiveness of Preference-Based Quality-of-Life Measures in Informal Carers: A Comparison of 5 Measures Across 4 Conditions

    Jun 1, 2020, 00:00

  • An Investigation of the Stability of Patients’ Treatment Preferences Over the Course of a Clinical Trial [Editor's Choice]

    Jun 1, 2020, 00:00

  • Research and Policy Impact of Trials Published by the UK National Institute of Health Research (2006-2015) [Editor's Choice]

    Jun 1, 2020, 00:00

  • Application of Discrete-Event Simulation in Health Technology Assessment: A Cost-Effectiveness Analysis of Alzheimer’s Disease Treatment Using Real-World Evidence in Thailand

    Jun 1, 2020, 00:00

  • Peer Review and Transparency in Evidence-Source Selection in Value and Health Technology Assessment

    Jun 1, 2020, 00:00

  • Patient-Reported Morbidity Instruments: A Systematic Review

    Jun 1, 2020, 00:00

  • Advances in Value-Based Healthcare by the Application of Time-Driven Activity-Based Costing for Inpatient Management: A Systematic Review

    Jun 1, 2020, 00:00

  • Developing Markov Models From Real-World Data: A Case Study of Heart Failure Modeling Using Administrative Data

    Jun 1, 2020, 00:00

  • Copyright/Subscription

    Jun 1, 2020, 00:00

  • Associations Between End-of-Life Expenditures and Hospice Stay Length Vary by Clinical Condition and Expenditure Duration

    Jun 1, 2020, 00:00

  • Threshold for Computer- and Robot-Assisted Knee and Hip Replacements in the English National Health Service

    Jun 1, 2020, 00:00

  • Trauma Service Utilization Increases Cost But Does Not Add Value for Minimally Injured Patients

    Jun 1, 2020, 00:00

  • Acceptability and Validity of the EQ-5D in Patients Living With Dementia [Editor's Choice]

    Jun 1, 2020, 00:00

  • Defining Patient Engagement in Research: Results of a Systematic Review and Analysis: Report of the ISPOR Patient-Centered Special Interest Group [Editor's Choice]

    Jun 1, 2020, 00:00

  • Table of Contents

    Jun 1, 2020, 00:00

  • The Effects of Model Misspecification in Unanchored Matching-Adjusted Indirect Comparison: Results of a Simulation Study

    Jun 1, 2020, 00:00

  • Computing the Expected Value of Sample Information Efficiently: Practical Guidance and Recommendations for Four Model-Based Methods [Editor's Choice]

    Jun 1, 2020, 00:00

  • Response Shift–Adjusted Treatment Effect on Health-Related Quality of Life in a Randomized Controlled Trial of Taxane Versus S-1 for Metastatic Breast Cancer: Structural Equation Modeling

    Jun 1, 2020, 00:00

  • Editorial Board

    May 7, 2020, 09:00

  • PGI12 COMPARISON OF BURDEN OF HOSPITALIZATIONS IN CROHN'S DISEASE AND ULCERATIVE COLITIS: A PROPENSITY SCORE MATCHED ANALYSIS OF IN-PATIENT CLAIMS DATABASE

    May 1, 2020, 00:00

  • PIN40 MANAGEMENT OF HIV/AIDS IN BRAZIL: A SYSTEMATIC REVIEW ON TREATMENT ADHERENCE AND ITS IMPACT ON RESOURCE UTILIZATION AND COSTS

    May 1, 2020, 00:00

  • PMD2 HEALTH OUTCOMES ASSOCIATED WITH DIFFERENT TRANSFUSION MODALITIES IN SICKLE CELL DISEASE

    May 1, 2020, 00:00

  • PDG2 ASSOCIATION BETWEEN POTENTIALLY INAPPROPRIATE MEDICATIONS AND HOSPITAL ENCOUNTERS AMONG OLDER ADULTS: A META-ANALYSIS

    May 1, 2020, 00:00

  • PIH41 EPIDEMIOLOGICAL DISEASE BURDEN OF ENDOMETRIOSIS BASED ON ROUTINELY COLLECTED HEALTH INSURANCE CLAIMS DATA

    May 1, 2020, 00:00

  • PDG12 THE LONG-TERM COST-EFFECTIVENESS OF VILDAGLIPTIN+ METFORMIN THERAPY RELATIVE TO COMPARATOR SULFONYLUREA+ METFORMIN THERAPY IN PATIENTS WITH TYPE 2 DIABETES IN CHINA

    May 1, 2020, 00:00

  • Diabetes/Endocrine/Metabolic Disorders - Health Technology Assessment

    May 1, 2020, 00:00

  • Diabetes/Endocrine/Metabolic Disorders - Health Service Delivery Process of Care

    May 1, 2020, 00:00

  • PDB100 PREDICTORS OF PERSISTENCE WITH INITIAL ANTIDIABETIC TREATMENT REGIMENS AMONG ADULT PATIENTS WITH TYPE 2 DIABETES: A NATIONWIDE RETROSPECTIVE COHORT STUDY

    May 1, 2020, 00:00

  • PIH60 MEDICATIONS RISK AND PREGNANCY: KNOWLEDGE, ATTITUDE, AND PRACTICE OF PHARMACISTS IN GONDAR TOWN, NORTH WEST ETHIOPIA. A CROSS-SECTIONAL STUDY

    May 1, 2020, 00:00

  • PIH77 SOCIOECONOMIC INEQUALITY IN HIV PREVENTION AMONGST FEMALE SEX WORKERS: A CROSS-SECTIONAL ANALYSIS OF ORAL PRE-EXPOSURE PROPHYLAXIS IN RURAL KENYA

    May 1, 2020, 00:00

  • PMD36 ANALYSIS OF SAFETY ADVERSE REPORTING EVENTS OF ESSURE MEDICAL DEVICE: THE END ROAD OF ESSURE

    May 1, 2020, 00:00

  • PGI28 INFLUENCE OF PUBLISHED STUDIES ON SPONTANEOUS REPORTING OF ADVERSE KIDNEY EVENTS WITH PROTON PUMP INHIBITORS (PPIS)

    May 1, 2020, 00:00

  • PIH56 DEMOGRAPHIC CHARACTERISTICS AND EXPENDITURES ASSOCIATED WITH OBESITY CODES IN PRIVATELY INSURED CHILDREN, 2017

    May 1, 2020, 00:00

  • PMS39 COST-EFFECTIVENESS OF SECUKINUMAB IN THE TREATMENT OF ANKYLOSING SPONDYLITIS IN BRAZIL

    May 1, 2020, 00:00

  • PMH69 TOTAL COSTS OF DEPRESSION: RESULTS FROM THE UPPER-MIDDLE INCOME COUNTRY IN EU IN 2018

    May 1, 2020, 00:00

  • PMH3 ASSESSING THE PSYCHOLOGICAL DISTRESS (PD) IN THE ASIAN INDIAN (AI) MINORITY IN THE UNITED STATES

    May 1, 2020, 00:00

  • PIH11 OUT-OF-POCKET HEALTH EXPENDITURES RELATED TO PRENATAL CARE: EVIDENCE FROM COLOMBIA, 2018

    May 1, 2020, 00:00

  • PDB70 THE PREVALENCE OF MICROALBUMINURIA IN ADOLESCENTS WITH OBESITY IN UNITED STATES USING THE NATIONAL HEALTH AND NUTRITION EXAMINATION SURVEY (NHANES) DATA 2011-2016

    May 1, 2020, 00:00

  • PMU37 THE RESULTANT IMPACT OF HEOR DATA ON US PAYER FORMULARY COVERAGE

    May 1, 2020, 00:00

  • Gastrointestinal Disorders - Clinical Outcomes

    May 1, 2020, 00:00

  • PIH32 CLINICAL OUTCOMES AND HEALTHCARE EXPENDITURES IN THE FIRST YEAR OF LIFE AMONG INFANTS OF MOTHERS WITH PREECLAMPSIA: AN ANALYSIS OF LINKED MATERNAL AND INFANT INSURANCE CLAIMS

    May 1, 2020, 00:00

  • PIH81 UTERUS ENDOMETRIOSIS IN BRAZIL: TREATMENT PATTERNS AND COSTS IN THE PUBLIC HEALTHCARE BRAZILIAN SYSTEM

    May 1, 2020, 00:00

  • Medical Devices - Clinical Outcomes

    May 1, 2020, 00:00

  • PDB5 DOES THE ENCOUNTER TYPE MATTER WHEN DEFINING DIABETES COMPLICATIONS IN ELECTRONIC HEALTH RECORDS?

    May 1, 2020, 00:00

  • PB4 PROJECT HERCULES: A PATIENT LED PARADIGM IN EVIDENCE GENERATION FOR HTA IN DUCHENNE MUSCULAR DYSTROPHY

    May 1, 2020, 00:00

  • PMS84 PSYCHOMETRIC ANALYSIS OF THE PEDIATRIC QUALITY OF LIFE GENERIC CORE SCALE AND NEUROMUSCULAR MODULE IN DUCHENNE MUSCULAR DYSTROPHY: IMPLICATIONS FOR DETERMINING PATIENT-PERCEIVED TREATMENT BENEFIT

    May 1, 2020, 00:00

  • PIN93 REAL WORLD EVIDENCE IN ARGENTINA: TREATMENT OF PATIENTS WITH HEPATITIS C IN THE PROTECTIVE SYSTEM OF EMERGING SANITARY TECHNOLOGIES (PSEST)

    May 1, 2020, 00:00

  • Mental Health - Organizational Practices

    May 1, 2020, 00:00

  • PDB7 ASSESSMENT OF CARDIOVASCULAR OUTCOMES ASSOCIATED WITH SODIUM GLUCOSE COTRANSPORTER 2 (SGLT2) INHIBITOR THERAPY AND INCRETIN-BASED THERAPIES AMONG ELDERLY PATIENTS TYPE 2 DIABETES MELLITUS

    May 1, 2020, 00:00

  • Drugs Generics - Health Technology Assessment

    May 1, 2020, 00:00

  • PDB37 COST-EFFECTIVENESS OF ACARBOSE IN TREATING AND MANAGING CHINESE IMPAIRED GLUCOSE TOLERANCE (IGT) POPULATION

    May 1, 2020, 00:00

  • PIN17 ECONOMIC IMPACT OF 13-VALENT PNEUMOCOCCAL CONJUGATE VACCINE (PCV13) VERSUS NO VACCINATION IN ADULTS >60 YEARS, IN COSTA RICAN SOCIAL SECURITY

    May 1, 2020, 00:00

  • PIH19 COST-EFFECTIVENESS OF THE DURATION OF NEONATAL EXTRACORPOREAL MEMBRANE OXYGENATION FOR NEWBORNS WITH SEVERE CONGENITAL DIAPHRAGMATIC HERNIA IN THE UNITED STATES

    May 1, 2020, 00:00

  • PMU31 ABSENTEEISM AND WORK DISABILITY ASSOCIATED WITH PSORIASIS AND PSORIATIC ARTHRITIS IN THE US

    May 1, 2020, 00:00

  • PDB79 INSULIN PRICES IN CANADA, SAUDI ARABIA, AND THE US.

    May 1, 2020, 00:00

  • PIN25 ESTIMATING THE POTENTIAL COST-EFFECTIVENESS OF CURATIVE HEPATITIS B IMMUNOLOGIC THERAPY IN THE UNITED STATES

    May 1, 2020, 00:00

  • Drugs Information Systems

    May 1, 2020, 00:00

  • Diabetes/Endocrine/Metabolic Disorders - Health Policy Regulatory

    May 1, 2020, 00:00

  • PDG21 THE GENERIC ENTRY AND MARKET SHARE COMPETITION OF STATINS MEDICATION USE: A RETROSPECTIVE TREND ANALYSIS OF UTILIZATION, SPENDING, AND PRICES IN THE UNITED STATES MEDICAID PROGRAMS FROM 1991 TO 2017

    May 1, 2020, 00:00

  • PDB91 ANTIHYPERLIPIDEMIC USE AMONG ADULTS AGED 40 YEARS AND MORE WITH TYPE 2 DIABETES: ASSESSMENT OF RACIAL DISPARITIES

    May 1, 2020, 00:00

  • PIH26 COST EFFECTIVENESS OF PALIVIZUMAB FOR RESPIRATORY SYNCYTIAL VIRUS PROPHYLAXIS AMONG EXTREME PRETERM INFANTS (29 WEEKS OF GESTATIONAL AGE) AT THE SOCIAL SECURITY MEXICAN INSTITUTE (IMSS)

    May 1, 2020, 00:00

  • Infectious Diseases - Health Service Delivery Process of Care

    May 1, 2020, 00:00

  • PMD12 THE BURDEN OF READMISSIONS IN THE POST-OPERATIVE POPULATION IN THE US: THE INFLUENCE OF MANAGEMENT WITH AN OSCILLATING POSITIVE EXPIRATORY PRESSURE DEVICE

    May 1, 2020, 00:00

  • PGI37 THRESHOLDS FOR MEANINGFUL CHANGE FOR THE EQ-5D VAS AND EORTC QLQ-C30 PHYSICAL AND ROLE FUNCTIONING SCALE IN GASTROINTESTIONAL-RELATED CANCERS

    May 1, 2020, 00:00

  • PMS80 EXAMINATION OF THE CORE- AND PERINEAL MUSCLES IN CASE OF DIFFERENT MOVEMENTS

    May 1, 2020, 00:00

  • Author's Reply

    May 1, 2020, 00:00

  • PDB58 REAL WORLD EVIDENCE ON THE IMPACT OF ELAGOLIX UTILIZATION ON PAIN SYMPTOMS, TREATMENT PATTERNS AND HEALTH RESOURCE USE AMONG ENDOMETRIOSIS PATIENTS IN THE UNITED STATES

    May 1, 2020, 00:00

  • PMS5 EARLY CARE DECISIONS AND THE RISK OF LONG-TERM OPIOID USE IN PATIENTS WITH LOW BACK PAIN

    May 1, 2020, 00:00

  • PDG28 ANALYSIS OF MARIJUANA AND OPIOID USE AMONG CANCER PATIENTS IN THE U.S.

    May 1, 2020, 00:00

  • Drugs Generics - Clinical Outcomes

    May 1, 2020, 00:00

  • PMU17 COST-EFFECTIVENESS OF IMPLEMENTING ROUTINE HEARING SCREENING USING A TABLET AUDIOMETER FOR PEDIATRIC CYSTIC FIBROSIS PATIENTS RECEIVING HIGH-DOSE AMINOGLYCOSIDES

    May 1, 2020, 00:00

  • PDB2 HEALTH-RELATED QUALITY OF LIFE AND SLEEP QUALITY AMONG NORTH INDIAN TYPE 2 DIABETES MELLITUS PATIENTS: EVIDENCE FROM A CROSS-SECTIONAL STUDY

    May 1, 2020, 00:00

  • PDB19 COST-EFFECTIVENESS ANALYSIS OF INSULIN DEGLUDEC/INSULIN ASPART VERSUS INSULIN GLARGINE IN PATIENTS WITH TYPE 2 DIABETES IN CHINA

    May 1, 2020, 00:00

  • PDB98 THE IMPACT OF SEVERE VASOMOTOR SYMPTOMS ON WORK PRODUCTIVITY AND ACTIVITY IMPAIRMENT: FINDINGS FROM A US REAL WORLD SURVEY

    May 1, 2020, 00:00

  • PIN31 BUDGET-IMPACT ANALYSIS OF IBALIZUMAB IN THE TREATMENT OF US MEDICARE BENEFICIARIES WITH MULTIDRUG-RESISTANT HIV-1 INFECTION

    May 1, 2020, 00:00

  • PMS41 THE ECONOMIC BURDEN OF MUSCULOSKELETAL DISORDERS RESULTING FROM ROAD TRAFIC ACCIDENT IN LOW AND MIDDLE INCOME COUNTRIES: A SYSTEMATIC REVIEW

    May 1, 2020, 00:00

  • PBI8 ESTIMATE OF COSTS OF THE BRAZILIAN MINISTRY OF HEALTH WITH THE SUPPLY OF BIOLOGICAL MEDICINES FOR SPONDYLOARTHRITIS IN THE PUBLIC HEALTH SYSTEM, IN 2017

    May 1, 2020, 00:00

  • PCN6 REAL-WORLD CLINICAL OUTCOMES AND HOSPITAL COSTS ASSOCIATED WITH POWERED STAPLER IN VIDEO-ASSISTED THORACIC SURGERY LOBECTOMY FOR LUNG CANCER IN A CHINESE TERITARY CARE HOSPITAL

    May 1, 2020, 00:00

  • PMH65 CHARACTERIZATION OF PATIENTS WITH AND/OR MEETING DSM-5 CRITERIA FOR BINGE EATING DISORDER

    May 1, 2020, 00:00

  • PCN3 RETROSPECTIVE ELECTRONIC HEALTH RECORDS STUDY IN THE CANCERLINQ DISCOVERY DATABASE OF TREATMENT PATTERNS AMONG PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA

    May 1, 2020, 00:00

  • PDB49 THE IMPLICATIONS OF SOARING INSULIN COST FOR DIABETES POPULATION ON US PAYERS

    May 1, 2020, 00:00

  • PDB30 HOSPITALIZATIONS AND COMORBIDITIES IN CHRONIC GOUT WITH AND WITHOUT TOPHUS: A PROPENSITY SCORE MATCHED ANALYSIS OF IN-PATIENT CLAIMS DATABASE

    May 1, 2020, 00:00

  • Cost-Effectiveness of Radiofrequency Denervation for Patients With Chronic Low Back Pain: The MINT Randomized Clinical Trials

    May 1, 2020, 00:00

  • PDG34 RISK SHARING AGREEMENTS: A POTENTIEL SOLUTION TO IMPROVE MARKET ACCESS TO INNOVATIONS IN ALGERIAN HOSPITAL SECTOR

    May 1, 2020, 00:00

  • PMD29 HOSPITAL VARIATIONS IN THE USE OF ROBOTIC-ASSISTED SURGERIES IN THE U.S. PEDIATRIC POPULATION

    May 1, 2020, 00:00

  • PMU24 PROPORTIONAL SHORTFALL - AN ALTERNATIVE APPROACH TO QALY ESTIMATION WITHIN ECONOMIC EVALUATION

    May 1, 2020, 00:00

  • Understanding the Patient Experience of Severe, Recurrent, Bilateral Nasal Polyps: A Qualitative Interview Study in the United States and Germany

    May 1, 2020, 00:00

  • PBI36 REVIEW AND COMPARISON OF OVERALL SURVIVAL EXTRAPOLATION IN HEALTH TECHNOLOGY ASSESSMENTS FOR CHIMERIC ANTIGEN RECEPTOR T-CELL THERAPIES (CAR-TS)

    May 1, 2020, 00:00

  • PDB109 DIABETES IN ARGENTINA: ANALYSIS OF DIABETES AND ITS COMPLICATIONS IN THE SOCIAL SECURITY SYSTEM

    May 1, 2020, 00:00

  • PMS27 CONCEPTUAL FRAMEWORK FOR ECONOMIC EVALUATION OF KNEE KINESIOGRAPHY FOR THE MANAGEMENT OF KNEE OSTEOARTHRITIS

    May 1, 2020, 00:00

  • PGI10 BUDGET IMPACT ANALYSIS OF INCORPORATING ENDOSCOPIC CAPSULE FOR DIAGNOSIS OF OBSCURE GASTROINTESTINAL BLEEDING IN THE BRAZILIAN PRIVATE HEALTHCARE SYSTEM

    May 1, 2020, 00:00

  • PMS14 ANNUAL HEALTH INSURANCE TREATMENT COST OF INJURIES TO THE WRIST AND HAND BASED ON ROUTINELY COLLECTED REAL-WORLD FINANCING DATA

    May 1, 2020, 00:00

  • PCV53 EFFECTIVENESS OF A CARDIOVASCULAR RISK MANAGEMENT PROGRAM IN THE INCIDENCE OF CARDIOVASCULAR EVENTS IN A LOW-INCOME POPULATION FROM THE CARIBBEAN REGION OF COLOMBIA

    May 1, 2020, 00:00

  • Gastrointestinal Disorders - Epidemiology Public Health

    May 1, 2020, 00:00

  • PDG23 PRESCRIPTION DRUG ABUSE ACROSS THE LIFESPAN

    May 1, 2020, 00:00

  • PAM5 EFFICACY OF VACUOTHERAPY (CUPPING OR CUPPING THERAPY) IN OSTEOMUSCULAR PATHOLOGY

    May 1, 2020, 00:00

  • PDB88 MEASURING INSULIN ADHERENCE USING ADJUSTED MEDICATION POSSESSION RATIO: AN EXAMINATION OF THE METHODOLOGY

    May 1, 2020, 00:00

  • PMS50 EPIDEMIOLOGICAL DISEASE BURDEN OF SCOLIOSIS BASED ON ROUTINELY COLLECTED HEALTH INSURANCE CLAIMS DATA

    May 1, 2020, 00:00

  • Drugs Process of Care

    May 1, 2020, 00:00

  • Reviewer Acknowledgement

    May 1, 2020, 00:00

  • PIN43 HEALTH CARE RESOURCE UTILIZATION AND COST OF HEAVILY TREATMENT EXPERIENCED (HTE) PEOPLE LIVING WITH HIV (PLWH) IN US COMMERCIAL AND MEDICARE ADVANTAGE HEALTH PLANS

    May 1, 2020, 00:00

  • PDG19 COST-EFFECTIVENESS OF OBINUTUZUMAB-CHEMOTHERAPY FOLLOWED BY OBINUTUZUMAB MAINTENANCE COMPARED TO RITUXIMAB-CHEMOTHERAPY FOLLOWED BY RITUXIMAB MAINTENANCE IN A CHILEAN HEALTH PUBLIC SYSTEM SETTING FOR NON-HODGKIN-LYMPHOMA PATIENT’S

    May 1, 2020, 00:00

  • PGI40 REAL-WORLD MEDICATION USE AND COST OF ILLNESS IN REFLUX ESOPHAGITIS IN THE CHINESE SETTING

    May 1, 2020, 00:00

  • PDB82 DIRECT COST AND CLINICAL OUTCOMES ASSOCIATED WITH BARIATRIC SURGERY INTERVENTION, OF PATIENTS WITH OBESITY DIAGNOSIS, IN A HEALTH INSURANCE COMPANY IN COLOMBIA.

    May 1, 2020, 00:00

  • PDB62 INTERACTION OF HOUSEHOLD AND NEIGHBORHOOD SOCIOECONOMIC STATUS IN THE CHILDHOOD OBESITY EPIDEMIC IN THE UNITED STATES

    May 1, 2020, 00:00

  • PDG62 HEALTH STATE UTILITIES OF PEOPLE WHO USE OPIOIDS REGURLARLY IN NEW SOUTH WALES, VICTORIA AND TASMANIA, AUSTRALIA: ARE THEY RELATED TO DRUG HISTORY AND OPIOID SUBSTITUTION THERAPY?

    May 1, 2020, 00:00

  • PMH18 REVIEW AND CRITIC OF METHODS FOR ECONOMIC EVALUATION OF DIGITAL MENTAL HEALTH INTERVENTIONS

    May 1, 2020, 00:00

  • PBI21 TRENDS IN AUTHORIZATIONS AND PRICES OF BIOSIMILAR PRODUCTS IN THE US

    May 1, 2020, 00:00

  • AI3 PREDICTION OF BREAST CANCER USING K-NEAREST NEIGHBOUR: A SUPERVISED MACHINE LEARNING ALGORITHM

    May 1, 2020, 00:00

  • PDG72 ASSOCIATION BETWEEN THE INABILITY TO OBTAIN NECESSARY PRESCRIPTION MEDICAL CARE AND FUTURE HEALTHCARE EXPENDITURES IN THE MEDICAL EXPENDITURE PANEL (2015-2017)

    May 1, 2020, 00:00

  • PCV82 DEVELOPMENT AND VALIDATION OF A METHOD TO EXTRACT LEFT VENTRICULAR EJECTION FRACTION DATA FROM EHR PHYSICIAN NOTES

    May 1, 2020, 00:00

  • PMU29 REAL-WORLD IMPACT OF DISEASE ON FUNCTIONING AND ACTIVITY: A CROSS-SECTIONAL STUDY OF THE NATIONAL HEALTH AND NUTRITION EXAMINATION SURVEY

    May 1, 2020, 00:00

  • PMS93 CHARACTERIZING THE NATURAL HISTORY OF DUCHENNE MUSCULAR DYSTROPHY IN THE UNITED STATES IN REAL-WORLD COMMERCIAL AND MEDICAID DATA

    May 1, 2020, 00:00

  • PDB52 IMPACT OF USING DIFFERENT TYPES OF HBA1C PROGRESSION IN THE IQVIA CORE DIABETES MODEL

    May 1, 2020, 00:00

  • PMD21 ROBOTIC-ASSISTED TOTAL HIP REPLACEMENT: A 90-DAY EPISODE OF CARE ANALYSIS

    May 1, 2020, 00:00

  • Cardiovascular Disorders - Methodological Statistical Research

    May 1, 2020, 00:00

  • PGI14 ECONOMIC BURDEN ATTRIBUTABLE TO CLOSTRIDIOIDES DIFFICILE INFECTION OUTSIDE THE UNITED STATES: RESULTS FROM A SYSTEMATIC LITERATURE REVIEW

    May 1, 2020, 00:00

  • PMH42 ACOS AND PREVENTABLE HOSPITALIZATIONS AMONG PATIENTS WITH DEPRESSION

    May 1, 2020, 00:00

  • PIH33 POTENTIALLY INAPPROPRIATE PRESCRIBING OF PROTON-PUMP INHIBITORS AMONG OLDER PATIENTS IN THE U.S.

    May 1, 2020, 00:00

  • PDB84 INSULIN-RELATED OUT-OF-POCKET PHARMACY COSTS BEFORE AND AFTER HUMAN REGULAR U-500 INSULIN INITIATION VIA INSULIN PEN IN U.S. PATIENTS WITH TYPE 2 DIABETES

    May 1, 2020, 00:00

  • PMS59 EPIDEMIOLOGICAL DISEASE BURDEN OF PETROCHANTERIC FRACTURE BASED ON ROUTINELY COLLECTED HEALTH INSURANCE CLAIMS DATA

    May 1, 2020, 00:00

  • How Are Incremental Cost-Effectiveness, Contextual Considerations, and Other Benefits Viewed in Health Technology Assessment Recommendations in the United States? [Editor's Choice]

    May 1, 2020, 00:00

  • Medical Devices - Patient-Centered Research

    May 1, 2020, 00:00

  • PDB106 ESTABLISHMENT OF HEMOGLOBIN A1C PREDICTION MODEL IN PATIENTS TYPE 2 DIABETES MELLITUSESTABLISHMENT OF HEMOGLOBIN A1C PREDICTION MODEL IN PATIENTS WITH TYPE 2 DIABETES MELLITUS

    May 1, 2020, 00:00

  • PDB76 EPIDEMIOLOGICAL DISEASE BURDEN OF NON-INSULIN-DEPENDENT DIABETES WITH NEUROLOGICAL COMPLICATIONS BASED ON ROUTINELY COLLECTED HEALTH INSURANCE CLAIMS DATA

    May 1, 2020, 00:00

  • PDG65 OPIOID USE DISORDER AND HEALTH-RELATED QUALITY OF LIFE

    May 1, 2020, 00:00

  • PCN10 MACHINE LEARNING PREDICTION OF SURVIVAL IN DIFFUSE LARGE B-CELL LYMPHOMA BASED ON GENE-EXPRESSION PROFILING

    May 1, 2020, 00:00

  • Multiple Diseases - Conceptual Papers (CP)

    May 1, 2020, 00:00

  • Table of Contents

    May 1, 2020, 00:00

  • PIN11 COST-EFFECTIVENESS OF BEZLOTOXUMAB AND FIDAXOMICIN FOR RECURRENT C. DIFFICILE INFECTION

    May 1, 2020, 00:00

  • PMU42 A DECLINE IN PRESCRIPTION OPIOID ANALGESICIS AMONG NEWLY DIAGNOSED CHRONIC PAIN PATIENTS: A TREND IN THE RIGHT DIRECTION

    May 1, 2020, 00:00

  • PMS35 REAL-WORLD HEALTHCARE RESOURCE UTILIZATION AND ECONOMIC BURDEN IN PARTIAL TEAR PATIENTS MANAGED ON CONSERVATIVE THERAPY

    May 1, 2020, 00:00

  • PIH22 COST OF DELIVERING A HOME-BASED BEHAVIORAL INTERVENTION FOR PERSONS WITH DEMENTIA AND THEIR CAREGIVERS THROUGH THE CONNECTICUT HOME CARE PROGRAM FOR ELDERS

    May 1, 2020, 00:00

  • PMH14 BURDEN OF HOSPITALIZATIONS IN NARCOLEPSY PATIENTS WITH LOW AND HIGH COMORBIDITY INDEX: A PROPENSITY SCORE MATCHED ANALYSIS OF IN-PATIENT CLAIMS DATABASE

    May 1, 2020, 00:00

  • PIN85 PSYCHOMETRICS OF AN INSTRUMENT TO MEASURE PHARMACISTS PERSPECTIVES TOWARDS HIV PATIENT CARE IN AMBULATORY SETTINGS

    May 1, 2020, 00:00

  • PMS8 A SYSTEMATIC REVIEW OF SPECIALIZED PRO-RESOLVING LIPID MEDIATORS (SPMS) IN OSTEOARTHRITIS

    May 1, 2020, 00:00

  • PIN74 THE CLINICAL PHARMACIST-LED CONSULTATION FOR INFECTIOUS DISEASES IN GUIZHOU PROVINCE, CHINA: A SURVEY AMONG HOSPITAL PHARMACIES

    May 1, 2020, 00:00

  • PIH51 NON-CLINICAL FACTORS ARE THE KEY BARRIER FOR PATIENT ACCESS TO PENILE PROSTHESIS IN EMPLOYER-SPONSORED HEALTH INSURANCE

    May 1, 2020, 00:00

  • PGI18 COST-EFFECTIVENESS OF BIOLOGICS FOR MODERATE TO SEVERE ULCERATIVE COLITIS IN BRAZIL

    May 1, 2020, 00:00

  • Diabetes/Endocrine/Metabolic Disorders - Clinical Outcomes

    May 1, 2020, 00:00

  • PMU67 IMPACT OF PHARMACIST-PROVIDED TRANSITION OF CARE SERVICES ON HOSPITAL READMISSIONS

    May 1, 2020, 00:00

  • PCV85 EFFECT OF CHEST PAIN CENTER ON THE TREATMENT OF PATIENTS WITH ACUTE ST-SEGMENT ELEVATION MYOCARDIAL INFARCTION IN TIANJIN, CHINA

    May 1, 2020, 00:00

  • PCN2 PROJECTED LIFETIME CLINICAL VALUE OF A MULTICANCER EARLY DETECTION TEST

    May 1, 2020, 00:00

  • PMS37 ANNUAL HEALTH INSURANCE TREATMENT COST OF PETROCHANTERIC FRACTURE BASED ON ROUTINELY COLLECTED FINANCING DATA

    May 1, 2020, 00:00

  • PMD18 DIAGNOSTIC AND TREATMENT PATTERNS FOR WOMEN UNDERGOING ENDOMETRIAL BIOPSY AFTER A DIAGNOSIS OF POSTMENOPAUSAL BLEEDING

    May 1, 2020, 00:00

  • PMS90 EFFICIENCY TEST OF USING AN UNSTABLE TOOL ON CORE MUSCLES AMONG PRIMARY SCHOOL STUDENTS

    May 1, 2020, 00:00

  • PDB8 STUDY ON STANDARD CRITERIA OF SERUM URIC ACID AND FACTORS OF HIGH URIC ACID IN CHILDREN USING CLAIMS DATABASE IN JAPAN

    May 1, 2020, 00:00

  • Drugs Public Health

    May 1, 2020, 00:00

  • PMU40 VALIDATION OF AN ICD-10 CODING ADAPTATION FOR THE CHARLSON COMORBIDITY INDEX IN UNITED STATES HEALTHCARE ADMINISTRATIVE DATA

    May 1, 2020, 00:00

  • PMH44 INVESTIGATION OF BUPRENORPHINE TREATMENT ACCESS PROVIDED BY WAIVERED CLINICIANS

    May 1, 2020, 00:00

  • PBI11 TRENDS IN LIST PRICES, NET PRICES, AND DISCOUNTS FOR SELF-ADMINISTERED DISEASE-MODIFYING THERAPIES FOR MULTIPLE SCLEROSIS

    May 1, 2020, 00:00

  • PMS24 ANNUAL HEALTH INSURANCE TREATMENT COST OF FRACTURE OF SKULL AND FACIAL BONES BASED ON ROUTINELY COLLECTED REAL-WORLD FINANCING DATA

    May 1, 2020, 00:00

  • Infectious Diseases - Health Policy Regulatory

    May 1, 2020, 00:00

  • PMS15 HEALTH CARE RESOURCE UTILIZATION IN PATIENTS WITH SPONDYLOARTHRITIS: A SINGLE SETTING ANALYSIS IN COLOMBIA

    May 1, 2020, 00:00

  • PIH54 PROVISION OF CONTRACEPTIVES AS A MARKER OF POST-PARTUM QUALITY OF CARE AMONG WOMEN ENROLLED IN MEDICAID

    May 1, 2020, 00:00

  • PDG73 REGISTERED PURCHASE PROFILE OF NUSINERSEN IN THE BRAZILIAN DATABANK OF HEALTHCARE PRICES

    May 1, 2020, 00:00

  • PBI13 TRENDS IN LIST PRICES, NET PRICES, AND DISCOUNTS OF SELF-ADMINISTERED TUMOR NECROSIS FACTOR INHIBITORS

    May 1, 2020, 00:00

  • PDB31 DIRECT MEDICAL COSTS OF INCIDENT COMPLICATIONS IN PATIENTS WITH NEWLY-DIAGNOSED TYPE 2 DIABETES IN CHINA: FINDINGS FROM A MEDICAL CLAIMS DATABASE

    May 1, 2020, 00:00

  • PDB89 OBESITY PUBLICATION PATTERNS OVER 20 YEARS: WEIGHING DOWN OBESITY DRUG AVAILABILITY?

    May 1, 2020, 00:00

  • Musculoskeletal Disorders - Clinical Outcomes

    May 1, 2020, 00:00

  • PMU68 ASSESSING THE EFFECT OF THE DIETICIAN PROGRAM FOR MEMBERS WITH CHRONIC DISEASES AT BLUE CROSS BLUE SHIELD OF LOUISIANA

    May 1, 2020, 00:00

  • PMU25 EXCESS DIRECT HEALTHCARE EXPENDITURES ASSOCIATED WITH CO-EXISTING DEPRESSION AND ANXIETY AMONG ADULTS WITH NON-CANCER CHRONIC PAIN CONDITIONS (NCPC) IN THE UNITED STATES

    May 1, 2020, 00:00

  • Injury Trauma - Patient-Centered Research

    May 1, 2020, 00:00

  • PMH47 INTEGRATED PHARMACY BENEFITS ARE ASSOCIATED WITH REDUCED TOTAL MEDICAL SPENDING FOR MEMBERS WITH MENTAL HEALTH CONDITIONS: A BCBSLA PERSPECTIVE

    May 1, 2020, 00:00

  • The EQ-5D-5L Value Set for England: Findings of a Quality Assurance Program

    May 1, 2020, 00:00

  • PIN18 ARE WE FULLY CAPTURING THE SOCIAL IMPACT OF VACCINES?

    May 1, 2020, 00:00

  • PMU55 UNDERSTANDING STAKEHOLDER PERSPECTIVES ON DRUG AFFORDABILITY: EVALUATING USE AND APPLICATION IN VALUE-BASED CARE

    May 1, 2020, 00:00

  • PMU63 EXPLORING THE SYMPTOMATOLOGY OF DEPRESSION AND ITS EFFECT ON HEALTHCARE EXPENDITURES AND QUALITY OF LIFE OF DIABETIC PATIENTS

    May 1, 2020, 00:00

  • PMH6 DERIVING CLINICAL OUTCOME MEASURES FROM EXPRESSION AND SPEECH: RESULTS OF A PROOF OF CONCEPT STUDY

    May 1, 2020, 00:00

  • PDB72 THE PREVALENCE OF MICROVASCULAR COMPLICATIONS IN PATIENTS WITH TYPE 2 DIABETES MELLITUS IN CHINA: A SYSTEMATIC REVIEW AND META-ANALYSIS

    May 1, 2020, 00:00

  • PDG74 AVAILABILITY OF FDA-APPROVED SURROGATE MARKERS IN REAL-WORLD DATA

    May 1, 2020, 00:00

  • PMH30 PREVALENCE AND FACTORS ASSOCIATED WITH NARCOTIC CONTROLLED SUBSTANCE USE AMONG PEOPLE WITH DEPRESSION AND ANXIETY: NHANES 2015-2016

    May 1, 2020, 00:00

  • PIN37 INFLUENZA VACCINATION COSTS IN FRENCH HOSPITALS: A DECISION-TREE MODEL.

    May 1, 2020, 00:00

  • PMS32 A COST EFFECTIVENESS ASSESSMENT OF DUAL MOBILITY BEARINGS IN REVISION HIP ARTHROPLASTY

    May 1, 2020, 00:00

  • PMH49 PREDICTORS OF TIME TO OUTPATIENT FOLLOW-UP AND COSTS AFTER HOSPITALIZATION AMONG MEDICAID BENEFICIARIES UTILIZING ORAL VERSUS LONG-ACTING INJECTABLE ANTIPSYCHOTICS IN BIPOLAR DISORDER OR SCHIZOPHRENIA

    May 1, 2020, 00:00

  • PCN8 COMPARING PATIENT-RELEVANT ENDPOINT WITH CLINICAL ENDPOINT IN A RARE DISEASE: THE CASE OF METASTATIC MERKEL CELL CARCINOMA TREATED WITH AVELUMAB

    May 1, 2020, 00:00

  • PMS47 CONSISTENCY BETWEEN ANTICHOLINERGIC BURDEN SCALES IN THE ELDERLY WITH FRACTURES

    May 1, 2020, 00:00

  • Musculoskeletal Disorders - Methodological Statistical Research

    May 1, 2020, 00:00

  • Gastrointestinal Disorders - Health Policy Regulatory

    May 1, 2020, 00:00

  • PMS66 A NOVEL VISUAL TOOL TO UNDERSTAND THE TREATMENT PATTERNS AMONG TREATMENT-NAÏVE PSORIATIC ARTHRITIS PATIENTS PRESCRIBED BIOLOGICS IN THE US VETERANS HEALTH ADMINISTRATION POPULATION

    May 1, 2020, 00:00

  • PDB61 MULTIVARIATE LOGISTIC REGRESSION APPLIED TO CLINICAL EFFECTIVENESS IN THE DIABETES PREVENTION PROGRAM (DPP)

    May 1, 2020, 00:00

  • PIN91 INEQUALITY OF OPPORTUNITY IN PREVENTION OF MALARIA IN PREGNANCY: THE CASE OF LAKE VICTORIA REGION AND COASTAL MALARIA STABLE AREAS IN KENYA

    May 1, 2020, 00:00

  • PDB25 COST-EFFECTIVENES OF REAL-WORLD USE OF GLP-1 RECEPTOR AGONISTS VERSUS OTHER GLUCOSE-LOWERING AGENTS IN TYPE 2 DIABETES

    May 1, 2020, 00:00

  • Drugs Generics - Medical Technologies

    May 1, 2020, 00:00

  • PDB90 T2D PATIENTS PREDICTIVE MODELS OF MEDICATION NON-ADHERENCE RISKS BASED ON MULTIPLE MACHINE LEARNING ALGORITHMS

    May 1, 2020, 00:00

  • Musculoskeletal Disorders - Economic Evaluation

    May 1, 2020, 00:00

  • PMS48 EPIDEMIOLOGICAL DISEASE BURDEN OF INJURIES TO THE ANKLE AND FOOT BASED ON ROUTINELY COLLECTED HEALTH INSURANCE CLAIMS DATA

    May 1, 2020, 00:00

  • PMD52 ECONOMIC AND CLINICAL OUTCOMES OF SPINAL FUSION SURGERIES WITH SKIN CLOSURE THROUGH SKIN STAPLES PLUS WATERPROOF WOUND DRESSINGS VERSUS 2-OCTYL CYANOACRYLATE PLUS POLYMER MESH TAPE

    May 1, 2020, 00:00

  • PMU57 REGULATORY JOURNEY OVER TIME: A SYSTEMATIC MAPPING OF THE ‘FARMÁCIA POPULAR’ PROGRAM

    May 1, 2020, 00:00

  • PMD26 A COST-EFFECTIVENESS AND SENSITIVITY ANALYSIS OF METAL NEEDLES COMPARED WITH PLASTIC FISTULA CANNULAS FOR HEMODIALYSIS PATIENTS IN MEXICO, CONSIDERING NEEDLE-INDUCED INJURY REQUIRING INTERVENTION

    May 1, 2020, 00:00

  • PMD7 ONE-YEAR COMPLICATIONS AND REIMBURSEMENT AFTER INTRAMEDULLARY NAIL FIXATION FOR DISTAL FEMUR FRACTURES AMONG THE MEDICARE POPULATION

    May 1, 2020, 00:00

  • PIH74 EFFECTS OF EXPOSURE TO FIRST-HAND SMOKE, SECOND-HAND SMOKE AND THIRD-HAND SMOKE ON QUALITY OF LIFE IN PREGNANT WOMEN: A NATIONAL-BASED STUDY

    May 1, 2020, 00:00

  • Individual's Health - Clinical Outcomes

    May 1, 2020, 00:00
  • «
  • 31
  • 32
  • 33
  • 34
  • 35
  • 36
  • 37
  • 38 (current)
  • 39
  • 40
  • »